The team examined how the timing of statin therapy affected dementia rates over a median follow‑up of 7.1 years.

Adults who started a statin within one year of their diabetes diagnosis showed a 15% lower relative risk of developing dementia over the next ten years compared with those who did not begin treatment within five years. Those who waited one to five years still enjoyed a 10% lower relative risk.

Statins are prescription drugs that lower "bad" LDL cholesterol and are known to reduce heart attacks and strokes. People with type 2 diabetes already face higher risks of vascular problems and cognitive decline, which is why many guidelines recommend statins for adults aged 40‑75 with diabetes, even though the medication is not always started right away.

Dr. Liron Sinvani, a geriatrician and director for research and innovation at the Northwell Institute for Healthy Aging in New York, described the work as a "well‑designed, large‑scale observational study" and said the 15% reduction is "very significant," while reminding readers that the study shows an association, not a proven cause‑and‑effect relationship.

The findings were presented at the European Society of Cardiology Congress in Munich on Aug. 30 and later published in The Lancet Regional Health – Europe, adding to growing evidence that early cholesterol control might protect brain health.

Because the research is observational, doctors should view early statin use as one piece of a broader strategy that also includes a healthy diet, regular exercise and social engagement.